Completed PHASE1 INTERVENTIONAL 4-arm NCT02406066

Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

Phase 1 Combined Single and Multiple Rising Dose Study of the Safety and Pharmacokinetics of Metyrapone/Oxazepam Combination (EMB-001)

Sponsor: Embera NeuroTherapeutics, Inc.

Conditions Cocaine Use Disorder Tobacco Use Disorder

Interventions Placebo metyrapone & oxazepam

Updated 6 times since 2017 Last updated: Jul 21, 2016 Started: Mar 31, 2015 Primary completion: Dec 31, 2015 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cocaine Use Disorder and Tobacco Use Disorder and is currently completed. Embera NeuroTherapeutics, Inc. leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Embera NeuroTherapeutics, Inc.
National Institute on Drug Abuse (NIDA)

Data source: Embera NeuroTherapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baton Rouge, United States
• Long Beach, United States